Our research is focused in the areas of inflammation and immunology, and our pipeline of internally discovered programs is targeted to address significant patient needs.
Key Programs
We apply insights and innovation at each stage of our business and utilize our internal capabilities and those of our partners around the world. The table below summarizes the status of our key programs for internal development or co-development.
Economic Interests
We have an economic interest in potential future payments from GSK pursuant to its agreements with Innoviva, Inc. relating to certain respiratory programs, plus certain other programs that have been out-licensed or divested which do not require further economic investment by Theravance Biopharma.
*The information regarding the Trelegy Ellipta programs is based solely upon publicly available information and may not reflect the most recent developments under the programs.
Glossary
COPD
Chronic Obstructive Pulmonary Disease
cSSSI
Complicated Skin and Skin Structure Infections
FF
Fluticasone Furoate
HABP/VABP
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
IV
Intravenous
JAK inhibitor
Janus kinase inhibitor
nOH
Neurogenic Orthostatic Hypotension
POGD
Post-operative Gastrointestinal Dysfunction
UMEC
Umeclidinium
VI
Vilanterol
STATUS
The most advanced stage of clinical development that has been completed or is in process
PHASE 1
Initial clinical safety testing into patients or healthy human volunteers, or studies directed toward understanding the mechanisms of action of the drug
PHASE 2
Further clinical safety testing and preliminary efficacy testing in a limited patient population
PHASE 3
Evaluation of clinical efficacy and safety within an expanded patient population
FILED
A marketing application has been submitted to a regulatory authority
APPROVED
Approved for marketing in one or more countries